Indications
Treatment of moderate to severe thyroid eye disease (TED).
Composition
- Active substance
- teprotumumab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Tepezza
- Active substance
- teprotumumab
- ATC code
- L04AG13
- Therapeutic area
- Graves Ophthalmopathy
- Marketing authorisation holder
- Amgen Europe B.V.
- Status
- Authorised
- EU authorisation
- 19 Jun 2025
- EMA product number